title: Characteristics of pancreas transplantation currently performed in japan.
abstract: The Pancreas Transplantation (tx) Program under the Japanese Organ Transplant Act was started in 2000. PTx is indicated for type 1 diabetic patients on hemodialysis therapy. As of April 2003 93 patients are listed as candidates. Ten cases of PTx with enteric or bladder-drained technique were performed during the last 3 years as well as nine SPK and one PAK. Of 10 cases, nine recipients are insulin-free with HbA1c values ranging from 4.4% to 5.7%, although exogenous insulin was required in six cases temporarily, namely for a median 63 days (12 to 225 days). One case was lost due to pancreatic graft thrombosis. All 10 kidney grafts are functioning. Based on the experiences with 14 cases of pancreas tx using non-heart-beating (NHB) donors, we defined the criteria of NHB donor as: age younger than 40 years and cessation of respiratory support. One case of SPK with graft of NHB donor was done, and the recipient is off insulin. Pancreas and kidney are allocated for SPK if the recipient shares at least one HLA-DR antigen. Marginal donors were defined as higher mean donor age, median 37 (range 18 to 58 years); mean 38 +/- 12 years), and no death cause of by trauma. The revascularization of gastroduodenal artery to the pancreatic graft was performed in eight cases to minimize the risk of ischemic injury to the pancreatic graft and technical failure in cases of marginal donor.
authors.affiliation: Department of Urology, Nara Medical University, Kashihara, Japan. imichio@nmu-gw.naramed-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Ishibashi
authors.forename: T
authors.initials: T
authors.lastname: Ito
authors.forename: A
authors.initials: A
authors.lastname: Sugitani
authors.forename: K
authors.initials: K
authors.lastname: Nakajima
authors.forename: T
authors.initials: T
authors.lastname: Abe
authors.forename: N
authors.initials: N
authors.lastname: Matsuno
authors.forename: Y
authors.initials: Y
authors.lastname: Hirao
authors.forename: M
authors.initials: M
authors.lastname: Gotoh
authors.forename: M
authors.initials: M
authors.lastname: Tanaka
authors.forename: S
authors.initials: S
authors.lastname: Teraoka
authors.forename: H
authors.initials: H
authors.lastname: Matsuda
authors.forename: H
authors.initials: H
authors.lastname: Taniguchi
authors.forename: T
authors.initials: T
authors.lastname: Fukao
authors.forename: R
authors.initials: R
authors.lastname: Kikkawa
authors.forename: Y
authors.initials: Y
authors.lastname: Idezuki
authors.forename: Y
authors.initials: Y
authors.lastname: Kanazawa
mesh_terms: D000328:Adult; D001926:Brain Death; D003404:Creatinine / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery*; D003928:Diabetic Nephropathies / Q000628:therapy; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007328:Insulin / Q000627:therapeutic use; D007564:Japan; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016035:Pancreas Transplantation / Q000502:physiology / Q000706:statistics & numerical data*; D006435:Renal Dialysis; D016896:Treatment Outcome
chemical_list: D003404:Creatinine; D006442:Glycated Hemoglobin; D007328:Insulin